Pelvic Organ Prolapse After Menopause: What the Collagen Research Shows

• What is actually giving way when the pelvic floor drops?
• How common is pelvic organ prolapse after menopause?
• Is prolapse tissue short of collagen or making the wrong kind?
• What does losing estrogen do to the tissue that holds everything up?
• What does shilajit's own research show about type I collagen?
• Common questions about pelvic organ prolapse and collagen

What is actually giving way when the pelvic floor drops?

The organs in the pelvis are not held up by muscle alone. They are suspended by sheets and ligaments of connective tissue, and that tissue is mostly collagen.

Jackson and colleagues (1996) took vaginal epithelial tissue from women with genitourinary prolapse and compared it with tissue from women without. What they found was not a tired muscle. It was a tissue being taken apart faster than it was being rebuilt.

Five things separated the prolapse tissue from the control tissue in that paper.

• Total collagen content was reduced
• Collagen solubility was decreased, meaning the remaining collagen behaved differently
• Intermediate intermolecular cross-links were increased
• Advanced glycation cross-links were increased
• Collagen turnover, measured as matrix metalloproteinase activity, ran up to four times higher

Their conclusion was blunt. Increased collagenolytic activity causes loss of collagen from prolapse tissue.

Why the cohort in that study matters

The women Jackson's team biopsied were premenopausal.

That single detail does a lot of work. It means the collagen defect was already measurable before estrogen withdrawal, which rules out the idea that prolapse is purely a menopause problem. Menopause is better understood as the stress test that finds tissue which was already running close to its limit.

How common is pelvic organ prolapse after menopause?

Far more common than the silence around it suggests.

Hendrix and colleagues (2002) ran a baseline pelvic examination on 27,342 women enrolled in the Women's Health Initiative hormone trial. Read the numbers slowly, because they are not small.

• Among the 16,616 women who still had a uterus, 14.2 percent had uterine prolapse
• 34.3 percent of that same group had a cystocele, a drop in the front vaginal wall
• 18.6 percent had a rectocele, a drop in the back wall
• Among the 10,727 women who had undergone hysterectomy, 32.9 percent had a cystocele
• Parity and obesity were both strongly associated with increased risk

Roughly one in three women examined had some degree of front wall prolapse. That figure came from an examination, not from a list of complaints the women brought in.

Is prolapse tissue short of collagen or making the wrong kind?

Here the literature splits, and the split is the most useful thing in it.

Moalli and colleagues (2005) took full thickness biopsies from the vaginal apex of 77 women at the time of surgery, comparing 15 premenopausal controls against 62 women with prolapse. They did not replicate the simple collagen deficit.

Total collagen in prolapsed tissue was slightly higher, at a p value of 0.054 that did not quite reach statistical significance, and the increase was driven by type III collagen specifically. Active MMP-9, another collagen-degrading enzyme, was increased in the prolapse group.

Type I and type III do different jobs

The two studies reconcile once you stop counting collagen and start asking which kind it was.

Type I collagen is the tensile one. It is the rope. Type III is thinner, more compliant and laid down quickly, which makes it the body's fast repair material. Tissue under chronic strain lays down more type III because it is rebuilding constantly.

More total collagen made mostly of the stretchier kind is not a stronger sheet. It is a patched one.

What does losing estrogen do to the tissue that holds everything up?

Estrogen is deeply involved in connective tissue maintenance, and the honest answer is more complicated than the marketing on either side of this question.

Hansen and colleagues (2009) used a stable isotope tracer in postmenopausal women to measure the actual rate at which tendon collagen was being synthesized. Women on estrogen therapy were synthesizing collagen at a markedly higher resting rate than non-users, at a p value below 0.001. Estrogen clearly participates in keeping female connective tissue turning over.

The limits of that study deserve saying out loud. The tendons of the estrogen users were no bigger and no denser, and a second collagen marker showed no difference between the groups. What was higher was the resting synthesis rate, which is a rate of work rather than a finished structure.

Then there is the trial that biopsied pelvic tissue directly, and it went the other way.

Jackson and colleagues (2002) randomized 55 postmenopausal women to oral estradiol or placebo for 6 months, with periurethral biopsies before and after. Against placebo, total collagen fell, the mature cross-link HHL fell, and MMP-2, the enzyme that degrades collagen, rose.

How to hold both results at once

Different tissue, different timescale, different outcome. The tendon work measured a synthesis rate over a habitual course. The pelvic work measured structural content after 6 months of a single oral dose in women who already had symptoms.

What neither study supports is the simple claim that replacing the hormone rebuilds the sheet.

What does shilajit's own research show about type I collagen?

The limit goes first, before anything else in this section. No trial of shilajit has ever tested a prolapse outcome, and nothing here claims otherwise.

What shilajit does have is human data on the exact protein these biopsies keep pointing at.

Neltner and colleagues (2024), publishing in the Journal of Dietary Supplements, ran an 8-week randomized controlled trial in 35 recreationally trained men with a mean age of 21.1 years. Circulating collagen levels rose 94 percent in 8 weeks while the placebo group stayed flat. It is type I collagen, the tensile kind, and the participants were young men rather than postmenopausal women.

Das and colleagues (2016) went further upstream, into the tissue itself. In adults taking oral shilajit for 8 weeks, muscle biopsies showed a cluster of 17 extracellular matrix genes significantly upregulated against baseline, confirmed by RT-PCR.

Read the list of what was in that cluster and the relevance becomes obvious.

• Collagen, the structural rope of the support sheet
• Elastin, the protein that lets tissue recoil after being stretched
• Fibrillin 1, which organizes elastic fibres into working bundles
• Fibronectin 1, decorin and tenascin XB, which govern how fibres are assembled
• Supplementation was well tolerated, with no change in glucose, lipids or muscle damage markers

That was skeletal muscle, not pelvic fascia, and gene activity is not the same thing as a repaired ligament. It does answer a narrower question, which is whether shilajit reaches the connective tissue machinery at all. In that tissue, in those adults, it did.

Shilajit is not a hormone and it does not add estrogen to the body. The research points to its fulvic acid supporting the body's own estrogen signaling, which is the system that falls quiet at menopause.

Optimum Shilajit

We are family owned, out of Florida, and every box carries a 90 day money-back guarantee. Optimum Shilajit

See Optimum Shilajit